Factors predicting biochemical response and survival benefits following radioligand therapy with [Lu-177]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
In: 10.1007/s00259-021-05237-y
- Event
-
Veröffentlichung
- (where)
-
Aachen
- (who)
-
Universitätsbibliothek der RWTH Aachen
- (when)
-
2021
- Creator
-
Manafi-Farid, Reyhaneh
Harsini, Sara
Saidi, Bahare
Ahmadzadehfar, Hojat
Herrmann, Ken
Briganti, Alberto
Walz, Jochen
Beheshti, Mohsen
- DOI
-
10.18154/RWTH-CONV-248446
- URN
-
urn:nbn:de:101:1-2023052501404768180177
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
25.03.2025, 1:49 PM CET
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Manafi-Farid, Reyhaneh
- Harsini, Sara
- Saidi, Bahare
- Ahmadzadehfar, Hojat
- Herrmann, Ken
- Briganti, Alberto
- Walz, Jochen
- Beheshti, Mohsen
- Universitätsbibliothek der RWTH Aachen
Time of origin
- 2021
Other Objects (12)
![Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer](/assets/placeholder/searchResultMediaUnknown.png)
Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Safety and survival utcomes of 177 Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate Cancer with prior 223 Ra treatment: the RALU study
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
[177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Safety and survival utcomes of 177 Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate Cancer with prior 223 Ra treatment: the RALU study
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
[177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer
Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer
Matched-pair analysis of [\(^177}\)Lu]Lu-PSMA I&T and [\(^177}\)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
An intrapatient dosimetry comparison of 177 Lu-rhPSMA-10.1 and 177 Lu-PSMA-I&T in patients with metastatic castration-resistant prostate cancer
Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer
Hematotoxicity and nephrotoxicity in prostate cancer patients undergoing radioligand therapy with [\(^177}\)Lu]Lu-PSMA I&T
⁶⁸Ga-PSMA PET for the assessment of metastatic prostate cancer
Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving 177Lu-PSMA-617 Radioligand Therapy
Outcome of 177Lu-PSMA-617 radioligand therapy in chemo-refractory patients with metastatic castration-resistant early-onset prostate cancer
Safety and survival utcomes of 177 Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate Cancer with prior 223 Ra treatment: the RALU study
Salvage radioligand therapy with repeated cycles of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer with diffuse bone marrow involvement
[177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer